CELU
Celularity Inc.
There isn't enough reported data to score CELU yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
CELU Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Unavailable | |
| Unavailable |
CELU's revenue and profitability are currently under pressure. There isn't enough data to rate its cash flow and balance sheet.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
CELU PE Valuation
CELU has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
CELU Forward outlook
There aren't enough analyst estimates for CELU to show an outlook.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
CELU Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.69 | +$1.48 |
| Q1 2026 | -$2.73 | -$0.28 |
| Q4 2025 | -$3.59 | -$0.95 |
CELU is still losing money, but far less than before: $1.69 per share over the past year, against $9.60 at its worst in late 2023.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over CELU in the latest year-over-year earnings comparison.
CELU Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $5.4M | -5.3% |
| Q1 2026 | $3.8M | -66% |
| Q4 2025 | $4.1M | -77% |
| Q3 2025 | $5.3M | -43% |
| Q2 2025 | $5.7M | -53% |
| Q1 2025 | $11.4M | -22% |
| Q4 2024 | $18.1M | +50% |
| Q3 2024 | $9.3M | +146% |
CELU's revenue has slid since its 2024 peak: $5M last quarter, down 5.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -78% | +199 points |
| Q1 2026 | -263% | -172 points |
| Q4 2025 | -537% | -486 points |
| Q3 2025 | -244% | -120 points |
| Q2 2025 | -277% | -193 points |
| Q1 2025 | -92% | -42 points |
| Q4 2024 | -51% | -161 points |
| Q3 2024 | -124% | +2498 points |
CELU's operating margin was −78% last quarter, up 199 points from the same quarter a year ago.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over CELU on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over CELU on profitability, with a higher operating margin.
CELU Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | -$5.1M | -432% |
| Q4 2024 | $1.5M | +$6.5M |
| Q3 2024 | -$179K | +$8.4M |
| Q2 2024 | -$3.5M | +$7.6M |
| Q1 2024 | -$4.4M | +$10.8M |
| Q4 2023 | -$4.9M | +$25.4M |
| Q3 2023 | -$8.6M | +$30.7M |
| Q2 2023 | -$11.1M | +$26.7M |
CELU has the stronger cash trend. Its trailing FCF is up 93% versus its history, compared with UNH at up 5.2%.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH still generates free cash flow, though less than at its 2022 peak: $22.8B over the past year.
CELU Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -3.2% | -955K shares |
| 1 year | +25% | +5.8M shares |
| 3 years | +89% | +13.8M shares |
| 5 years | +3561% | +28.5M shares |
CELU has 29M diluted shares, up 25% from a year ago.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over CELU on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
CELU Net Leverage
CELU's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
CELU Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.3 | Neutral |
| Stochastic | 6.1 | Oversold |
CELU's weekly RSI is 39 (neutral) and its Stochastic is 6 (oversold).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
CELU PE vs Healthcare Sector
| Metric | CELU | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
CELU has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
CELU Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.13 | 40% below |
| 20 week MA | $1.04 | 35% below |
| 50 week MA | $1.12 | 39% below |
| 100 week MA | $1.63 | 58% below |
| 200 week MA | $2.85 | 76% below |
CELU is in a downtrend: it's below all five of its weekly moving averages, and 76% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over CELU on trend strength, trading above more of its moving averages.
CELU Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $99.5 | $118.0 | +19% |
| 2021 | $118.0 | $47.0 | -60% |
| 2022 | $47.0 | $11.5 | -76% |
| 2023 | $11.5 | $2.47 | -79% |
| 2024 | $2.47 | $2.24 | -9.3% |
| 2025 | $2.24 | $1.34 | -40% |
| 2026 YTD | $1.34 | $0.68 | -49% |
CELU has finished five years in a row lower, and it's down 49% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over CELU on returns for 2026, with the stronger performance.